Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Renal Cell Carcinoma

Journal Scan / Research · November 04, 2019

Real-World Effectiveness and Tolerability of Pazopanib for mRCC in Latin America

Advances in Therapy

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

George Yaghmour MD

Advances in Therapy
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America
Adv Ther 2019 Oct 19;[EPub Ahead of Print], D Queiroz Muniz, B Ratto, H Yang, J Zhao, M Jenkins, J Signorovitch, L Dezzani, P Salman, M Lema Medina, D Lopera, G Lerzo, C Del Castillo, M Chacon, A Martin, S Campos-Gomez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated